Novogene
Beijing
About Novogene
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help their clients realize their research goals in the rapidly evolving world of genomics. The company has become a world-leader in NGS services, with 1,800 employees and multiple locations across the globe. Novogene’s depth of experience has resulted in the ownership of 49 NGS-related patents, as well as the publishing of over 1850 customer research papers, often in well-respected publications such as Nature and Science. Company founder, Dr. Ruiqiang Li, is widely recognized as one of the world’s leading experts in genomics and bioinformatics, owning 12 patents and authoring over 90 peer-reviewed publications that have been cited >15,000 times. Best known for developing the software SOAP (Short Oligonucleotide Analysis Package) for ultra-fast sequence mapping, variation detection, and de novo genome assembly, Dr. Li has focused Novogene’s services on performing sequencing AND providing informatics to fully empower and enable their customers to move forward rapidly and effectively in their scientific endeavors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 501 – 1,000
- Estimated revenue: $1K – $10K
- Total funding: $74.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Nov 2016)
- Website: en.novogene.com
- Phone: +86-010-82837801
Industries & Categories
AgTech, Bioinformatics, Biotechnology, Life Science, Software
Social Profiles
Canonical: https://fsome.com/organization/novogene-126721 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.